Evidence map›Paper›PMID 37373190›Full record

ArticleInternational journal of molecular sciences2023

Shubhra Acharya, Andrew I Lumley, Lu Zhang, Mélanie Vausort, Yvan Devaux, On Behalf Of The Ncer-Pd Consortium

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shubhra AcharyaCardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, L-1445 Strassen, Luxembourg.ORCID 0000-0003-2904-6566
Andrew I LumleyCardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, L-1445 Strassen, Luxembourg.ORCID 0000-0001-5935-3327
Lu ZhangBioinformatics Platform, Luxembourg Institute of Health, L-1445 Strassen, Luxembourg.ORCID 0000-0001-7141-6730
Mélanie VausortCardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, L-1445 Strassen, Luxembourg.ORCID 0000-0002-5261-7729
Yvan DevauxCardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, L-1445 Strassen, Luxembourg.ORCID 0000-0002-5321-8543
On Behalf Of The Ncer-Pd Consortium
Luxembourg Institute of Health · LUUniversity of Luxembourg · LU

Funding

Fonds National de la Recherche AFR14566210Fonds National de la Recherche C14/BM/8225223Fonds National de la Recherche C17/BM/11613033Fonds National de la Recherche COVID-19/2020-1/14719577/miRCOVIDFonds National de la Recherche FNR/NCER13/BM/11264123
6 · The paper itself

Abstract

Finding novel biomarkers for Parkinson's disease (PD) is crucial for early disease diagnosis, severity assessment and identifying novel disease-modifying drug targets. Our study aimed at investigating the

Indexed as

Parkinson DiseaseBiomarkersCase-Control StudiesCross-Sectional StudiesGATA3 Transcription FactorHumansRNARNA, MessengerBiomarkersGATA3 protein, humanGATA3 Transcription FactorRNARNA, Messengerblood-based biomarkerdiagnosisGATA3Parkinson’s disease (PD)

Identifiers

PMID37373190
PMCPMC10298393
OpenAlexW4380631445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.